Incontinence & Overactive Bladder Health Center
Muscle Cells Cut Urinary Incontinence
April 26, 2009 -- Muscle cells taken from patients' own thighs can help reduce their treatment-resistant stress urinary incontinence.
It isn't a joke when, due to stress urinary incontinence, laughing or coughing makes your bladder uncontrollably leak urine. Most patients get help from exercises, behavioral training, and drug treatment; but many still leak too often.
Help may be on the way from a new therapy: taking muscle cells from the upper thigh and injecting them into the sphincter muscle that controls urine flow. The idea is to stimulate growth of new sphincter muscle cells via growth signals sent by the injected cells.
It just might work, suggest clinical trials sponsored by Cook MyoSite, the Cook Medical subsidiary that is developing the treatment. University of Toronto researcher Lesley K. Carr, MD, and colleagues treated 29 women with one or two injections of thigh muscle cells at various doses.
All of the women had stress urinary incontinence that had not improved over a year of standard therapy.
"Overall, urinary leaks were reduced after both injections," Carr reported at this week's annual meeting of the American Urological Association.
Of the 17 patients evaluated 12 months after the muscle-cell injections, 13 -- over three-fourths of the women -- had fewer stress leaks and less urinary urgency.
However, one woman had worse incontinence than she had before treatment. While none of the adverse effects of treatment was rated "serious," there was pain and bruising in the thigh, pain at the site of injection, and "mild and self-limiting urinary retention and urinary tract infection."
Despite these issues, 86% of patients chose to have a second muscle cell injection three months after the first.
American Urological Association spokesman Anthony Atala, MD, chairman of the Wake Forest University urology department and a leader in the field of tissue regeneration, said the study confirmed the muscle-cell treatment to be safe and effective.
"It is important to note that this therapy has few side effects and seems to improve symptoms for most patients in whom other therapies failed," Atala says in a news release.
Indication
Uroxatral® (alfuzosin HCl 10 mg extended-release tablets) is an alpha1-blocker for the treatment of the signs and symptoms of BPH.
Important Safety Information
Do not take UROXATRAL if you have liver problems or if you are taking antifungal drugs like ketoconazole or itraconazole, or HIV drugs like ritonavir.
UROXATRAL can cause a sudden drop in blood pressure, especially when starting treatment. This may lead to fainting, dizziness, and lightheadedness. Do not drive, operate machinery, or do any dangerous activity until you know how UROXATRAL will affect you. This is especially important if you already have a problem with low blood pressure or take medicines to treat high blood pressure. There may be an increased risk of low blood pressure and fainting when taking UROXATRAL in combination with blood pressure medication or nitrates, or erectile dysfunction medication.
If considering cataract surgery (clouding of the eyes), tell your eye surgeon that you are currently taking UROXATRAL or have previously been treated with an alpha-blocker.
Before taking UROXATRAL, tell your doctor if you have kidney problems.
Also, tell your doctor if you or any family member(s) have or take medications for a rare heart condition known as congenital prolongation of the QT interval.
BPH and prostate cancer can cause the same symptoms. However, UROXATRAL is not a treatment for prostate cancer.
The most common side effects with UROXATRAL are dizziness, upper respiratory tract infection, headache, and tiredness.
Please see UROXATRAL full prescribing information.



